Sunshine Biopharma, Inc. (SBFM)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Camille Sebaaly | CFO & Secretary | 695k | -- | 1959 |
Dr. Abderrazzak Merzouki | Chief Science Officer & Director | 340k | -- | 1964 |
Dr. Steve N. Slilaty Ph.D. | CEO, President & Chairman | 430k | -- | 1952 |
Mr. Marc Beaudoin | Chief Operating Officer | -- | -- | 1967 |
Mr. Malek Chamoun | Chief Development Officer | -- | -- | 1985 |
Mr. Robert G. Ferreira | President of Sunshine Bio Investments Inc | -- | -- | 1962 |
Sunshine Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 44
Description
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.
Corporate Governance
Recent Events
- Apr 23, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 28, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 06, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 05, 2024PRE 14C: Proxy StatementsSee Full Filing